Loading...
•
Jun 30, 2025
Astrana Health Q2 2025 Earnings Report
Astrana Health reported second quarter 2025 results with strong revenue growth and solid adjusted EBITDA performance.
Key Takeaways
Astrana Health delivered total revenue of 654800000 in Q2 2025, up approximately 35% year-over-year, with net income of 9400000 and adjusted EBITDA of 48100000. EPS was reported at 0.19 per share as the company continued to expand its value-based care operations and integrate the Prospect Health acquisition.
Total revenue grew 35% year-over-year to 654800000.
Adjusted EBITDA for the quarter was 48100000, at the high end of guidance.
Net income was 9400000 with EPS of 0.19 per share.
Care Partners revenue led growth, reflecting expanded risk contracts.
Revenue by Segment
Forward Guidance
Management reaffirmed full-year 2025 revenue and adjusted EBITDA guidance and provided expected ranges for Q3 2025.
Positive Outlook
- Reaffirmed full-year 2025 revenue guidance of $3.1B to $3.3B.
- Reaffirmed full-year adjusted EBITDA guidance of $215M to $225M.
- Delivered revenue and adjusted EBITDA at the high end of Q2 guidance.
- Expanded full-risk contracts representing a growing share of revenue.
- Completed Prospect Health acquisition to strengthen long-term growth.
Challenges Ahead
- EPS of $0.19 missed consensus expectations.
- Profitability pressures from integration and cost trends.
- Medical cost trends remained slightly elevated in some segments.
- Leverage remains above targeted levels post-acquisition.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...